T2 Biosystems Inc TTOO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TTOO is a good fit for your portfolio.
News
-
T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024
-
T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
-
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
-
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
-
T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates
-
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
-
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
-
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results
Trading Information
- Previous Close Price
- $2.74
- Day Range
- $2.70–2.94
- 52-Week Range
- $2.60–70.00
- Bid/Ask
- $2.85 / $2.90
- Market Cap
- $24.97 Mil
- Volume/Avg
- 140,182 / 306,215
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.99
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company’s products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 113
- Website
- https://www.t2biosystems.com
Valuation
|
Metric
|
TTOO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.99 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TTOO
|
|---|---|
Quick Ratio | 0.30 |
Current Ratio | 0.45 |
Interest Coverage | −8.37 |
Quick Ratio
TTOO
Profitability
|
Metric
|
TTOO
|
|---|---|
Return on Assets (Normalized) | −133.42% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −208.56% |
Return on Assets
TTOO
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Jkrpjfgcn | Tdyr | $209.3 Bil | |
DHR
| Danaher Corp | Gkbbqdnc | Blgcmj | $182.1 Bil | |
IQV
| IQVIA Holdings Inc | Sdmsghq | Nqpxlny | $43.4 Bil | |
IDXX
| IDEXX Laboratories Inc | Jkktfrnn | Nlhvsc | $41.0 Bil | |
A
| Agilent Technologies Inc | Xblxmmyfd | Clzj | $40.3 Bil | |
MTD
| Mettler-Toledo International Inc | Mnsbcttl | Vkfvdlp | $26.4 Bil | |
ICLR
| Icon PLC | Fjmnswx | Djvmvf | $24.8 Bil | |
ILMN
| Illumina Inc | Tnvqwvpn | Zgsccbd | $19.3 Bil | |
WAT
| Waters Corp | Rdcktwtkb | Myktv | $18.3 Bil | |
LH
| Laboratory Corp of America Holdings | Btntnywph | Wtbywx | $17.5 Bil |